02:20 PM EST, 11/13/2025 (MT Newswires) -- Clearmind Medicine ( CMND ) received final approval from Hadassah Medical Center in Jerusalem for its ongoing Phase 1/2a trial of CMND-100, an oral drug candidate based on the company's novel psychoactive compound targeting alcohol use disorder.

The first cohort treatment has been successfully completed, Clearmind said Thursday in a statement.

The multicenter study will evaluate the safety, tolerability, and pharmacokinetics of CMND-100, while also evaluating its potential to reduce alcohol cravings and consumption, the company said.

Price: 0.36, Change: +0.05, Percent Change: +15.02